Selective Inhibitors of Genotoxic Stress-Induced Ikk/nf-Kb Pathways

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes a new class of chemical compounds that selectively inhibit the activation of the IKK/NF-kappaB signaling pathway triggered specifically by genotoxic stress (such as DNA damage), while leaving other activation pathways of NF-κB largely unaffected. The compounds are designed for use as medicines, targeting diseases where such genotoxic stress-induced NF-κB activation is a key pathological factor—most notably, certain cancers which display resistance to conventional DNA-damaging therapies due to this pathway's activation. By focusing on a highly specific mode of inhibition, these compounds may help sensitize cancer cells to existing therapies without broadly suppressing immune function or causing severe side effects.

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of cancer types (such as breast, colon, ovarian, leukemia, and lymphomas) that develop resistance to DNA-damaging therapies (chemotherapy or radiation) mediated by the genotoxic stress-induced IKK/NF-κB pathway.
• Combination therapy with chemotherapy or radiotherapy to improve cancer treatment efficacy by overcoming NF-κB-mediated therapy resistance.
• Therapy for diseases associated with genomic instability due to DNA repair defects, possibly including certain neurodegenerative diseases and progeroid syndromes.
• Potential use in managing non-cancerous diseases tied to genotoxic stress and unwanted NF-κB activation, such as diabetes, reperfusion injury, stroke, and aging-related disorders.
• Cell-based research tools or assays to study genotoxic stress-induced NF-κB signaling, apoptosis, and DNA repair processes.

BenefitsContent extracted from patent full text and abstract with AI.

• Selectively inhibits only the genotoxic stress-induced pathway of NF-κB activation, minimizing interference with other NF-κB functions necessary for normal immune response.
• Reduces side effects and systemic toxicity compared to non-selective NF-κB inhibitors, making long-term or combination therapy more tolerable.
• Enhances the effectiveness of existing cancer therapies by sensitizing resistant tumor cells to DNA-damaging treatments, potentially improving survival rates.
• Decreases expression of anti-apoptotic proteins in cancer cells, promoting apoptosis (programmed cell death) in response to therapy.
• Broadens the patient population who can safely receive NF-κB-targeted therapies, including those who are sensitive to the adverse effects of current inhibitors.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to chemical compounds and their use as a medicament in the treatment of a disease associated with genotoxic stress-induced IKK/NF-ºB (NF-kappaB) activation. The invention further relates to a pharmaceutical composition comprising a compound of the invention for the treatment of a subject afflicted by a disease associated with genotoxic stress-induced IKK/NF-ºB activation.